Source

Commission Implementing Decision (EU) 2026/334 of 13 February 2026 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products with regards to Foeniculum vulgare (notified under document C(2026) 808)

Implementing Decision (EU) 2026/334 · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annex II to Decision 2008/911/EC is amended in accordance with the Annex to this Decision.

Article 2

Open ↗

This Decision is addressed to the Member States.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX In Annex II, the Community list entry on Foeniculum vulgare Miller subsp. vulgare var. vulgare , fructus and the Community list entry on Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus are replaced by the following: ‘ A. UNION LIST ENTRY ON FOENICULUM VULGARE MILLER SUBSP. VULGARE VAR. VULGARE , FRUCTUS Scientific name of the plant Foeniculum vulgare Miller subsp. vulgare var. vulgare Botanical family Apiaceae Herbal substance Bitter fennel, fruit Common name of herbal substance in all EU official languages BG (bulgarski): Горчиво резене, плод LT (lietuvių kalba): Kartieji pankolių, vaisiai CS (čeština): Plod fenyklu obecného pravého LV (latviešu valoda): Rūgtā fenheļa, augļi DA (dansk): Fennikel bitter MT (malti): Bużbież morr, frotta DE (Deutsch): Bitterer Fenchel NL (nederlands): Bittere venkel, vrucht EL (elliniká): Πικρού μάραθου καρπός PL (polski): Koper włoski odmiany gorzkiej, owoc EN (English): Bitter Fennel PT (português): Funcho-amargo, fruto ES (español): Hinojo amargo, fruto RO (română): Fenicul amar, fruct ET (eesti keel): Mõru apteegitill, vili SK (slovenčina): Plod fenikla horkého FI (suomi): Karvasfenkoli, hedelmä SL (slovenščina): Plod grenkega navadnega komarčka FR (français): Fenouil amer, fruit SV (svenska): Bitterfänkål, frö HR (hrvatski): Komorač gorki, plod IS (íslenska): Bitur fennel aldin HU (magyar): Keserű édeskömény, termés NO (norsk): Bitter fennikel IT (italiano): Finocchio amaro, frutto Herbal preparation(s) Not applicable European Pharmacopoeia monograph reference Bitter fennel – Foeniculi amari fructus (04/2013:0824) Indications Indication (1) Traditional herbal medicinal product for symptomatic treatment of mild, spasmodic gastro-intestinal complaints including bloating and flatulence. Indication (2) Traditional herbal medicinal product for symptomatic treatment of minor spasm associated with menstrual periods. Indication (3) Traditional herbal medicinal product used as an expectorant in cough associated with cold. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. Type of tradition European Specified strength Please see “Specified posology” Specified posology Indications (1) and (3) Adults and adolescents Single dose Herbal tea: 1,5 g of herbal substance in 250 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 4,5 g Children between 4 and 12 years of age Single dose Herbal tea: 1,0 g of herbal substance in 100 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 3,0 g For further information on the use in children between 4 and 12 years of age, see section “Special warnings and precautions for use”. The use is not recommended in children under 4 years of age (see section “Special warnings and precautions for use”). See section “Pharmaceutical particulars” for content of estragole. Indication (2) Adults and adolescents Single dose Herbal tea: 1,5 g of herbal substance in 250 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 4,5 g The use in children under 12 years of age is not recommended (see section “Special warnings and precautions for use”). See section “Pharmaceutical particulars” for content of estragole. Route of administration Oral use Duration of use or any restrictions on the duration of use Indications (1), (2) and (3) Adults and adolescents Not to be taken for more than 2 weeks. Indications (1) and (3) Children between 4 and 12 years of age For short-term use in mild transitory symptoms only (less than one week). If the symptoms persist during the use of the medicinal product, a doctor or a qualified health-care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance or to Apiaceae (Umbelliferae) family (aniseed, caraway, celery, coriander and dill) or to anethole. Hypersensitivity to mugwort pollen, due to cross-reactivity with fennel. Special warnings and precautions for use Indications (1) and (3) The use in children between 4 and 12 years of age is not recommended if the daily intake of estragole exceeds the guidance value of 1,0 μg/kg bw, unless justified by a risk assessment based on adequate safety data. The use is not recommended in children under 4 years of age due to the lack of adequate data. Indication (2) The use in children under 12 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Interactions with other medicinal products and other forms of interaction None reported Fertility, pregnancy, and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. There is evidence that trans -anethole is excreted in human breast milk. No fertility data available. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Allergic reactions to fennel, affecting the skin or the respiratory system, may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health-care practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars In the general population exposure to estragole should be kept as low as practically achievable. In pregnant and breast-feeding women, the daily intake of estragole should be below 0,05 mg/person per day. In children below 12 years of age, the daily intake of estragole should be below 1,0 μg/kg bw. For further details see the “ Public statement on the use of herbal medicinal products containing estragole ”*. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience Not applicable. * “Public statement on the use of herbal medicinal products containing estragole” of 12 May 2023 of the Committee on Herbal Medicinal Products, EMA/HMPC/137212/2005, Rev 1 Corr 1, available at: https://www.ema.europa.eu/en/documents/other/public-statement-use-herbal-medicinal-products-containing-estragole-revision-1_en.pdf . B. UNION LIST ENTRY ON FOENICULUM VULGARE MILLER SUBSP. VULGARE VAR. DULCE (MILL.) BATT. & TRAB., FRUCTUS Scientific name of the plant Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab. Botanical family Apiaceae Herbal substance Sweet fennel, fruit Common name of herbal substance in all EU official languages BG (bulgarski): Сладко резене, плод LT (lietuvių kalba): Saldieji pankolių, vaisiai CS (čeština): Plod fenyklu obecného sladkého LV (latviešu valoda): Saldā fenheļa, augļi DA (dansk): Fennikel sød MT (malti): Bużbież ħelu, frotta DE (Deutsch): Süßer Fenchel NL (nederlands): Zoete venkel, vrucht EL (elliniká): Γλυκού μάραθου καρπός PL (polski): Koper włoski odmiany słodkiej, owoc EN (English): Sweet fennel, fruit PT (português): Funcho-doce, fruto ES (español): Hinojo dulce, fruto RO (română): Fenicul dulce, fruct ET (eesti keel): Magus apteegitill, vili SK (slovenčina): Plod fenikla sladkého FI (suomi): Makeafenkoli, hedelmä SL (slovenščina): Plod sladkega navadnega komarčka FR (français): Fenouil doux, fruit SV (svenska): Sötfänkål, frö HR (hrvatski): Komorač slatki, plod IS (íslenska): Sæt fennel aldin HU (magyar): Édeskömény termés NO (norsk): Søt fennikel IT (italiano): Finocchio dolce, frutto Herbal preparation(s) Not applicable European Pharmacopoeia monograph reference Sweet fennel – Foeniculi dulcis fructus (04/2011:0825)) Indications Indication (1) Traditional herbal medicinal product for symptomatic treatment of mild, spasmodic gastro-intestinal complaints including bloating and flatulence. Indication (2) Traditional herbal medicinal product for symptomatic treatment of minor spasm associated with menstrual periods. Indication (3) Traditional herbal medicinal product used as an expectorant in cough associated with cold. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. Type of tradition European Specified strength Please see “Specified posology” Specified posology Indications (1) and (3) Adults and adolescents Single dose Herbal tea: 1,5 g of herbal substance in 250 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 4,5 g Children between 4 and 12 years of age Single dose Herbal tea: 1,0 g of herbal substance in 100 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 3,0 g For further information on the use in children between 4 and 12 years of age, see section “Special warnings and precautions for use”. The use is not recommended in children under 4 years of age (see section “Special warnings and precautions for use”). See section “Pharmaceutical particulars” for content of estragole. Indication (2) Adults and adolescents Single dose Herbal tea: 1,5 g of herbal substance in 250 ml of boiling water (steep for 15 minutes) as a herbal infusion, 3 times daily. Recommended daily dose: 4,5 g The use in children under 12 years of age is not recommended (see section “Special warnings and precautions for use”). See section “Pharmaceutical particulars” for content of estragole. Route of administration Oral use Duration of use or any restrictions on the duration of use Indications (1), (2) and (3) Adults and adolescents Not to be taken for more than 2 weeks. Indications (1) and (3) Children between 4 and 12 years of age For short-term use in mild transitory symptoms only (less than one week). If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance or to Apiaceae (Umbelliferae) family (aniseed, caraway, celery, coriander and dill) or to anethole. Hypersensitivity to mugwort pollen, due to cross-reactivity with fennel. Special warnings and precautions for use Indications (1) and (3) The use in children between 4 and 12 years of age is not recommended if the daily intake of estragole exceeds the guidance value of 1,0 μg/kg bw, unless justified by a risk assessment based on adequate safety data. The use is not recommended in children under 4 years of age due to the lack of adequate data. Indication (2) The use in children under 12 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Interactions with other medicinal products and other forms of interaction None reported Fertility, pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. There is evidence that trans- anethole is excreted in human breast milk. No fertility data available. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Allergic reactions to fennel, affecting the skin or the respiratory system, may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health-care practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars In the general population exposure to estragole should be kept as low as practically achievable. In pregnant and breast-feeding women, the daily intake of estragole should be below 0,05 mg/person per day. In children below 12 years of age, the daily intake of estragole should be below 1,0 μg/kg bw. For further details see the “ Public statement on the use of herbal medicinal products containing estragole ”*. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience Not applicable. * “Public statement on the use of herbal medicinal products containing estragole” of 12 May 2023 of the Committee on Herbal Medicinal Products, (HMPC) EMA/HMPC/137212/2005, Rev 1 Corr 1, available at: https://www.ema.europa.eu/en/documents/other/public-statement-use-herbal-medicinal-products-containing-estragole-revision-1_en.pdf .’.

Other acts of the same type

Council Decision (EU) 2017/1967 of 23 October 2017 on the position to be adopted, on behalf of the European Union, within the EEA Joint Committee concerning an amendment to Protocol 31 to the EEA Agreement, on cooperation in specific fields outside the four freedoms (The Union's preparatory action on defence research)Administrative Commission for the Coordination of Social Security Systems — Decision No E6 of 19 October 2017 concerning the determination of when an electronic message is considered legally delivered in the Electronic Exchange of Social Security Information (EESSI) system (Text with relevance for the EEA and for Switzerland.)Council Implementing Decision (CFSP) 2017/1909 of 18 October 2017 implementing Decision (CFSP) 2016/849 concerning restrictive measures against the Democratic People's Republic of Korea Council Decision (CFSP) 2017/1860 of 16 October 2017 amending Decision (CFSP) 2016/849 concerning restrictive measures against the Democratic People's Republic of Korea Council Decision (CFSP) 2017/1869 of 16 October 2017 on the European Union Advisory Mission in support of Security Sector Reform in Iraq (EUAM Iraq)Commission Implementing Decision (EU) 2017/1870 of 16 October 2017 on the publication of the reference of the European standard on electronic invoicing and the list of its syntaxes pursuant to Directive 2014/55/EU of the European Parliament and of the Council (Text with EEA relevance. )Council Decision (EU) 2017/1921 of 16 October 2017 on the position to be adopted on behalf of the European Union within the Joint CARIFORUM-EU Council of the Economic Partnership Agreement between the CARIFORUM States, of the one part, and the European Community and its Member States, of the other part, as regards the establishment of a list of arbitrators Council Decision (EU) 2017/1922 of 16 October 2017 on the position to be adopted on behalf of the European Union within the Joint CARIFORUM-EU Council of the Economic Partnership Agreement between the CARIFORUM States, of the one part, and the European Community and its Member States, of the other part, as regards the amendment of Annex IX to Protocol I Council Decision (EU) 2018/385 of 16 October 2017 on the signing, on behalf of the Union and of the Member States, and provisional application of the Protocol to the Partnership and Cooperation Agreement establishing a partnership between the European Communities and their Member States, of the one part, and the Kyrgyz Republic, of the other part, to take account of the accession of the Republic of Croatia to the European Union Council Decision (Euratom) 2018/386 of 16 October 2017 approving the conclusion, by the European Commission, on behalf of the European Atomic Energy Community, of the Protocol to the Partnership and Cooperation Agreement establishing a partnership between the European Communities and their Member States, of the one part, and the Kyrgyz Republic, of the other part, to take account of the accession of the Republic of Croatia to the European Union Commission Decision (EU) 2018/884 of 16 October 2017 on aid measure SA.32874 (2012/C) (ex SA.32874 (2011/NN)) implemented by Denmark (notified under document C(2017) 4461) (Text with EEA relevance.)Commission Implementing Decision (EU) 2017/1857 of 13 October 2017 on the recognition of the legal, supervisory and enforcement arrangements of the United States of America for derivatives transactions supervised by the Commodity Futures Trading Commission as equivalent to certain requirements of Article 11 of Regulation (EU) No 648/2012 of the European Parliament and Council on OTC derivatives, central counterparties and trade repositories (Text with EEA relevance. )

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview